Today: 27 January 2026
Subscribe
Browse Category

Healthcare Industry News 17 January 2026 - 25 January 2026

Intuitive Surgical stock slips into weekend after earnings beat, with tariffs and 2026 outlook in focus

Intuitive Surgical stock slips into weekend after earnings beat, with tariffs and 2026 outlook in focus

New York, Jan 24, 2026, 17:23 EST — The market has closed. Intuitive Surgical (ISRG.O) shares ended Friday 0.4% lower at $523.99, with investors digesting a quarterly beat offset by a weaker growth forecast and higher tariff expenses. U.S. markets remain closed until Monday, leaving the stock heading into the new week shadowed by two key uncertainties: the pace at…
25 January 2026
·····
Thermo Fisher (TMO) stock pulls back from a fresh high as Jan. 29 earnings loom

Thermo Fisher (TMO) stock pulls back from a fresh high as Jan. 29 earnings loom

New York, January 24, 2026, 16:07 EST — Market closed Shares of Thermo Fisher Scientific Inc dropped 2.11% on Friday, closing at $625.98 after hitting a 52-week high just the day before. The broader U.S. market ended the session mixed. Volume exceeded recent averages, indicating some investors were cashing out ahead of a busy week packed with catalysts. (MarketWatch) Thermo…
24 January 2026
·····
Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

COPENHAGEN, Jan 24, 2026, 20:49 (CET) — Market closed Novo Nordisk A/S Class B shares (NOVOb.CO) closed higher on Friday in Copenhagen and head into the new week on that note, boosted by early signs of strong demand for its Wegovy weight-loss drug. Much of Novo’s profit hinges on its obesity-drug franchise, making the stock a stand-in for the durability…
24 January 2026
·····
Boston Scientific stock price: BSX ends higher as Fitch turns credit outlook positive ahead of key catalysts

Boston Scientific stock price: BSX ends higher as Fitch turns credit outlook positive ahead of key catalysts

New York, Jan 23, 2026, 21:14 EST — Market closed Shares of Boston Scientific Corp ended Friday up 1.3% at $92.51. Late in the session, Fitch Ratings revised the medical-device maker’s outlook to Positive, while keeping its A- and F1 issuer ratings unchanged. Fitch noted this could pave the way for an upgrade to “A” once the company’s financials stabilize…
24 January 2026
·····
Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

New York, Jan 23, 2026, 11:35 ET — Regular session Eli Lilly shares dropped Friday, rattled by investor concerns after rival Novo Nordisk’s Wegovy pill recorded over 18,000 U.S. prescriptions in its first full week on shelves. (Reuters) This read-through is crucial: weight-loss drugs now account for a rising chunk of big pharma’s market value, and the fight is shifting…
23 January 2026
······
Intuitive Surgical Q4 2025 earnings beat lifts ISRG, but 2026 da Vinci forecast slows on tariffs

Intuitive Surgical Q4 2025 earnings beat lifts ISRG, but 2026 da Vinci forecast slows on tariffs

SUNNYVALE, Calif., Jan 22, 2026, 13:58 PST Intuitive Surgical topped Wall Street forecasts for Q4 profit and revenue on Thursday, buoyed by steady demand for its da Vinci surgical robots. The news pushed shares 3.3% higher in after-hours trading. (Reuters) Investors are shifting their attention from quarterly sales to procedure growth — the count of surgeries performed using the robots…
22 January 2026
·····
Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus

Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus

New York, Jan 22, 2026, 10:14 EST — Regular session Abbott Laboratories shares dropped 7.4%, hitting $111.74 in morning trading after falling as low as $106.13. The slide came on the back of a quarterly revenue miss and a cautious outlook on near-term profits. The decline is significant because it brings back a familiar challenge for Abbott: stabilizing nutrition and…
22 January 2026
·····
Thermo Fisher stock price rises nearly 2% as Australia starts Clario deal review; earnings next in focus

Thermo Fisher stock price rises nearly 2% as Australia starts Clario deal review; earnings next in focus

New York, January 21, 2026, 11:46 EST — Regular session Thermo Fisher Scientific Inc (NYSE: TMO) shares climbed roughly 1.9% to $630.48 Wednesday, outpacing the broader market as investors digested new regulatory developments around its planned Clario acquisition. The stock hit an intraday high of $631.25 earlier in the session. The Australian Competition and Consumer Commission (ACCC) has launched a…
21 January 2026
····
Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

New York, January 20, 2026, 14:46 EST — During the regular session Pfizer (PFE) shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That…
20 January 2026
······
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

New York, January 20, 2026, 14:02 EST — Regular session Merck & Co (MRK.N) shares held steady on Tuesday following news that the company’s personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda (pembrolizumab). By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating…
20 January 2026
·····
Intuitive Surgical stock slips as ISRG heads into key earnings call after softer 2026 outlook

Intuitive Surgical stock slips as ISRG heads into key earnings call after softer 2026 outlook

New York, Jan 20, 2026, 2:03 PM EST — Regular session Intuitive Surgical (ISRG.O) dipped roughly 1.5% to $526.76 in Tuesday afternoon trading, as U.S. stocks slipped broadly. The S&P 500 ETF dropped about 1.9%, and the Nasdaq 100 ETF lost close to 1.9%, though the healthcare sector showed much smaller declines. Intuitive Surgical shares remain in the spotlight as…
20 January 2026
·····
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Copenhagen, January 17, 2026, 21:05 CET — The market has closed. Shares of Novo Nordisk A/S Class B jumped 6.5%, finishing Friday at 388.9 Danish crowns. The late-week surge put the stock in a stronger position ahead of Monday’s market open. Trading volume hit roughly 13.9 million shares amid a session that shifted alongside the news cycle. (Investing) This move…
17 January 2026
·····
1 2 3 … 10

Stock Market Today

  • Lumine Group (TSXV:LMN) Faces Valuation Scrutiny Amid Share Price Drop
    January 26, 2026, 8:18 PM EST. Lumine Group's shares (TSXV:LMN) have fallen 31% over three months to CA$24.11, prompting questions about valuation. The stock trades at a price-to-earnings (P/E) ratio of 45.8x, above its Canadian software sector average of 45.2x and its peer group average of 42.5x, indicating an expensive valuation. Despite this, Lumine's discounted cash flow (DCF) model suggests a 19% intrinsic value discount, estimating fair value at CA$29.66. Investors face conflicting signals: a high P/E reflecting premium expectations for growth and profitability, against a DCF implying potential undervaluation. The company posted a 1-year total shareholder return of 36.55%, though recent trends show momentum fading with slowing net income growth. Market participants must weigh these factors carefully amid reassessment of Lumine's future prospects.
Go toTop